Gavreto
Chemical Name | pralsetinib |
Dosage Form | Capsules (oral; 100 mg) |
Drug Class | Kinase inhibitors |
System | Respiratory |
Company | Blueprint Medicines |
Approval Year | 2020 |
Indication
- To treat adult patients with non-small cell lung cancer (NSCLC) which has spread to other parts of the body (metastatic) and is caused by abnormal RET (rearranged during transfection) genes.